Loading...
Market
Story
Moderna Beats Q1 Estimates, Plans RSV Vaccine Launch Despite Revenue Drop
May 2, 2024, 12:05 PM
Moderna Inc. reported first-quarter earnings that surpassed analyst expectations, with earnings per share of $(3.07) beating estimates of $(3.55) and sales totaling $167 million, exceeding the forecast of $97.5 million. The company's revenue, however, saw a significant decline of 91% compared to the previous year, primarily due to a drop in Covid vaccine sales. Despite the decline, the revenue still topped expectations. Moderna's Spikevax vaccine generated $167 million in sales, including $100 million in U.S. sales and $67 million internationally. The company also announced plans to launch an RSV vaccine in the fall.
View original story
Similar markets
More than 20% • 50%
20% or less • 50%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
Below 50% • 25%
50% to 60% • 25%
60% to 70% • 25%
Above 70% • 25%
Moderna leads • 33%
GSK leads • 33%
Pfizer leads • 33%
GSK • 33%
Pfizer • 33%
Moderna • 34%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
Increased Moderna market share • 33%
No significant change • 34%
Decreased Pfizer/BioNTech market share • 33%